Charles Schwab Investment Management Inc. Sells 22,619 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Charles Schwab Investment Management Inc. trimmed its position in shares of Cryoport, Inc. (NASDAQ:CYRX) by 5.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 365,095 shares of the company’s stock after selling 22,619 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Cryoport were worth $2,840,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fred Alger Management LLC increased its holdings in shares of Cryoport by 49.9% in the third quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock worth $21,887,000 after acquiring an additional 898,481 shares in the last quarter. Geode Capital Management LLC increased its stake in Cryoport by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,097,369 shares of the company’s stock worth $8,902,000 after purchasing an additional 38,520 shares in the last quarter. State Street Corp raised its holdings in Cryoport by 2.8% during the 3rd quarter. State Street Corp now owns 1,003,080 shares of the company’s stock worth $8,135,000 after buying an additional 27,438 shares during the period. Point72 Asset Management L.P. bought a new position in Cryoport in the third quarter valued at approximately $3,405,000. Finally, Franklin Resources Inc. boosted its holdings in shares of Cryoport by 5.5% in the third quarter. Franklin Resources Inc. now owns 385,619 shares of the company’s stock valued at $3,127,000 after buying an additional 20,077 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.

Analysts Set New Price Targets

CYRX has been the topic of several research reports. Guggenheim initiated coverage on shares of Cryoport in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective on the stock. UBS Group raised Cryoport from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a research report on Monday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Cryoport in a report on Wednesday, March 5th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Cryoport has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Cryoport Price Performance

NASDAQ:CYRX opened at $6.24 on Friday. Cryoport, Inc. has a 52-week low of $4.58 and a 52-week high of $20.11. The company has a market cap of $311.44 million, a P/E ratio of -1.85 and a beta of 1.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The stock’s 50-day simple moving average is $6.71 and its 200 day simple moving average is $7.33.

Cryoport (NASDAQ:CYRX) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The company had revenue of $59.53 million for the quarter, compared to analyst estimates of $58.71 million. During the same period last year, the firm earned ($0.29) EPS. As a group, sell-side analysts forecast that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the transaction, the chief executive officer now directly owns 765,399 shares of the company’s stock, valued at $4,814,359.71. The trade was a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 19,830 shares of company stock valued at $118,353 over the last 90 days. 10.10% of the stock is currently owned by insiders.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.